0EGP
- Active ingredient
- sorafenib
- Strength
- 200 mg
- Form
- tablet
- Manufacturer
- cipla ltd. - india >
- Route
- oral.solid
Uses
Used for unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive iodine-refractory differentiated thyroid carcinoma.
Do not use if
Contraindicated in patients with severe hypersensitivity to sorafenib. Certain combinations are contraindicated in specific cancer settings.
Side effects
Common adverse effects include hypertension, diarrhea, rash, hand-foot skin reaction, fatigue, and bleeding events.
Warnings
Monitor blood pressure, cardiovascular events, bleeding, skin toxicity, and gastrointestinal complications during treatment.
How it works
A multikinase inhibitor that blocks tumor cell proliferation and tumor angiogenesis by targeting several intracellular and surface kinases.
Storage
Store at room temperature in a dry place and protect from excessive heat.
